Brief: Hungary's Richter receives European Commission approval for Denosumab biosimilar products Junod and Yaxver
01/07/2025 07:05
July 1 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says: RECEIVES EUROPEAN COMMISSION APPROVAL FOR DENOSUMAB BIOSIMILAR PRODUCTS JUNOD AND YAXVER FOR BONE DISEASE AND OSTEOPOROSIS -STATEMENT JUNOD AND YAXVER ARE APPROVED FOR ALL INDICATIONS OF REFERENCE MEDICINES PROLIA AND XGEVA -STATEMENT Source text: [https://bet.hu/newkibdata/129284215/Denosumab%20EC_July_2025_ENG.pdf] Further company coverage: GDRB.BU (Reporting by Anita Komuves) ((KOMUVES.Anita@thomsonreuters.com;))
Recent news on Gedeon Richter
See all newsBrief: Hungary's Richter says US FDA accepted for review its new drug application for Fylrevy
Brief: Hungary's Richter Upgrades 2026 Pharma Clean EBIT Guidance To Double-Digit Growth
development partnership in Tirzepatide
AI in Hungary could unlock productivity gains of €15 billion, McKinsey says
Brief: Hungary's Richter and Hetero announce cooperation for development of semaglutide injection